Full Press Release Details
Notes to the Interim Financial Statements
six month period to 30 June 2021
("Tiziana" or "the Company")
Results for the Six Months Ended 30 June 2021
pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
24 September 2021 - Tiziana Life Sciences plc ("Tiziana", LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology
company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for
the six months ended 30 June 2021.
Notes to the Interim Financial Statements
for the six month period to 30 June 2021
Notes to the Interim Financial Statements
for the six month period to 30 June 2021
Notes to the Interim Financial Statements
for the six month period to 30 June 2021
Company continues to carefully manage its working capital position and continues the process, as referred to below, to evaluate opportunities
to raise further funds through the issue of additional equity capital.
view the complete Interim Accounts click here: https://ir.tizianalifesciences.com/financial-information/interim-reports
Tiziana Life Sciences
Life Sciences plc is a dual listed (NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of
novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will
be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally administered Foralumab for progressive
multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world.
This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's Disease, multiple
sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R")
mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.